176 related articles for article (PubMed ID: 38339343)
121. Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
González-López O; Muñoz-González JI; Orfao A; Álvarez-Twose I; García-Montero AC
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626091
[TBL] [Abstract][Full Text] [Related]
122. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
Naumann N; Lübke J; Shomali W; Reiter L; Horny HP; Jawhar M; Dangelo V; Fabarius A; Metzgeroth G; Kreil S; Sotlar K; Oni C; Harrison C; Hofmann WK; Cross NCP; Valent P; Radia D; Gotlib J; Reiter A; Schwaab J
Br J Haematol; 2021 Jul; 194(2):344-354. PubMed ID: 34060083
[TBL] [Abstract][Full Text] [Related]
123. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Zanotti R; Perkins C; Jawhar M; Sperr WR; Shoumariyeh K; Schwaab J; Greiner G; Henriques A; Caldas C; Fernández-Giménez C; Sánchez-Muñoz L; Mayado A; Pérez-Pons A; Schmitt-Graeff A; Duyster J; Tanasi I; Olivieri F; Mora-Casterá E; Luna I; Senent L; Bañas MH; Nuñez-García A; Jurado-Chacón M; Martín-Sánchez G; Colado E; Xicoy B; Gener-Ricós G; Gotlib J; Bonadonna P; Reiter A; Valent P; García-Montero AC; Orfao A
Lancet Haematol; 2021 Mar; 8(3):e194-e204. PubMed ID: 33508247
[TBL] [Abstract][Full Text] [Related]
124. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.
Sperr WR; Kundi M; Alvarez-Twose I; van Anrooij B; Oude Elberink JNG; Gorska A; Niedoszytko M; Gleixner KV; Hadzijusufovic E; Zanotti R; Bonadonna P; Bonifacio M; Perkins C; Illerhaus A; Elena C; Merante S; Shoumariyeh K; von Bubnoff N; Parente R; Jawhar M; Belloni Fortina A; Caroppo F; Brockow K; Zink A; Fuchs D; Kilbertus AJ; Yavuz AS; Doubek M; Hägglund H; Panse J; Sabato V; Bretterklieber A; Niederwieser D; Breynaert C; Hartmann K; Triggiani M; Nedoszytko B; Reiter A; Orfao A; Hermine O; Gotlib J; Arock M; Kluin-Nelemans HC; Valent P
Lancet Haematol; 2019 Dec; 6(12):e638-e649. PubMed ID: 31676322
[TBL] [Abstract][Full Text] [Related]
125. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.
Jawhar M; Schwaab J; Álvarez-Twose I; Shoumariyeh K; Naumann N; Lübke J; Perkins C; Muñoz-González JI; Meggendorfer M; Kennedy V; Metzgeroth G; Fabarius A; Pfeifer D; Sotlar K; Horny HP; von Bubnoff N; Haferlach T; Cross NCP; Hofmann WK; Sperr WR; García-Montero AC; Valent P; Gotlib J; Orfao A; Reiter A
J Clin Oncol; 2019 Nov; 37(31):2846-2856. PubMed ID: 31509472
[TBL] [Abstract][Full Text] [Related]
126. World Health Organization class-independent risk categorization in mastocytosis.
Pardanani A; Lasho TL; Reichard KK; Hanson CA; Tefferi A
Blood Cancer J; 2019 Mar; 9(3):29. PubMed ID: 30833549
[No Abstract] [Full Text] [Related]
127. Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.
Broderick V; Waghorn K; Langabeer SE; Jeffers M; Cross NCP; Hayden PJ
Leuk Res; 2019 Feb; 77():28-29. PubMed ID: 30612056
[No Abstract] [Full Text] [Related]
128. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.
Pardanani A; Shah S; Mannelli F; Elala YC; Guglielmelli P; Lasho TL; Patnaik MM; Gangat N; Ketterling RP; Reichard KK; Hanson CA; Vannucchi AM; Tefferi A
Blood Adv; 2018 Nov; 2(21):2964-2972. PubMed ID: 30413432
[TBL] [Abstract][Full Text] [Related]
129. A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.
Patnaik MM; Rangit Vallapureddy ; Lasho TL; Hoversten KP; Finke CM; Ketterling RP; Hanson CA; Gangat N; Tefferi A; Pardanani A
Leukemia; 2018 Aug; 32(8):1850-1856. PubMed ID: 29712989
[No Abstract] [Full Text] [Related]
130. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17
Alvarez-Twose I; Matito A; Morgado JM; Sánchez-Muñoz L; Jara-Acevedo M; García-Montero A; Mayado A; Caldas C; Teodósio C; Muñoz-González JI; Mollejo M; Escribano L; Orfao A
Oncotarget; 2017 Sep; 8(40):68950-68963. PubMed ID: 28978170
[TBL] [Abstract][Full Text] [Related]
131. Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome.
Jain P; Wang S; Patel KP; Sarwari N; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2017 Aug; 59():105-109. PubMed ID: 28599188
[TBL] [Abstract][Full Text] [Related]
132. Response and progression on midostaurin in advanced systemic mastocytosis:
Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
[TBL] [Abstract][Full Text] [Related]
133. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
Jawhar M; Schwaab J; Meggendorfer M; Naumann N; Horny HP; Sotlar K; Haferlach T; Schmitt K; Fabarius A; Valent P; Hofmann WK; Cross NCP; Metzgeroth G; Reiter A
Haematologica; 2017 Jun; 102(6):1035-1043. PubMed ID: 28255023
[TBL] [Abstract][Full Text] [Related]
134. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
Jawhar M; Schwaab J; Hausmann D; Clemens J; Naumann N; Henzler T; Horny HP; Sotlar K; Schoenberg SO; Cross NC; Fabarius A; Hofmann WK; Valent P; Metzgeroth G; Reiter A
Leukemia; 2016 Dec; 30(12):2342-2350. PubMed ID: 27416984
[TBL] [Abstract][Full Text] [Related]
135. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.
Arock M; Sotlar K; Akin C; Broesby-Olsen S; Hoermann G; Escribano L; Kristensen TK; Kluin-Nelemans HC; Hermine O; Dubreuil P; Sperr WR; Hartmann K; Gotlib J; Cross NC; Haferlach T; Garcia-Montero A; Orfao A; Schwaab J; Triggiani M; Horny HP; Metcalfe DD; Reiter A; Valent P
Leukemia; 2015 Jun; 29(6):1223-32. PubMed ID: 25650093
[TBL] [Abstract][Full Text] [Related]
136. Molecular defects in mastocytosis: KIT and beyond KIT.
Bibi S; Langenfeld F; Jeanningros S; Brenet F; Soucie E; Hermine O; Damaj G; Dubreuil P; Arock M
Immunol Allergy Clin North Am; 2014 May; 34(2):239-62. PubMed ID: 24745672
[TBL] [Abstract][Full Text] [Related]
137. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.
Valent P; Sotlar K; Sperr WR; Escribano L; Yavuz S; Reiter A; George TI; Kluin-Nelemans HC; Hermine O; Butterfield JH; Hägglund H; Ustun C; Hornick JL; Triggiani M; Radia D; Akin C; Hartmann K; Gotlib J; Schwartz LB; Verstovsek S; Orfao A; Metcalfe DD; Arock M; Horny HP
Ann Oncol; 2014 Sep; 25(9):1691-1700. PubMed ID: 24675021
[TBL] [Abstract][Full Text] [Related]
138. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.
Chan EC; Bai Y; Kirshenbaum AS; Fischer ER; Simakova O; Bandara G; Scott LM; Wisch LB; Cantave D; Carter MC; Lewis JC; Noel P; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM
J Allergy Clin Immunol; 2014 Jul; 134(1):178-87. PubMed ID: 24582309
[TBL] [Abstract][Full Text] [Related]
139. A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a Chinese family.
Wang HJ; Lin ZM; Zhang J; Yin JH; Yang Y
Clin Exp Dermatol; 2014 Mar; 39(2):146-9. PubMed ID: 24289326
[TBL] [Abstract][Full Text] [Related]
140. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
